Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

被引：10
|
作者：
Antonia, Scott [1 ]
Rizvi, Naiyer [2 ]
Brahmer, Julie [3 ]
Ou, Sai-Hong [4 ]
Khleif, Samir N. [5 ]
Hwu, Wen-Jen [6 ]
Gutierrez, Martin [7 ]
Schoffski, Patrick [8 ]
Hamid, Omid [9 ]
Weiss, Jared [10 ]
Lutzky, Jose [11 ]
Maio, Michele [12 ]
Nemunaitis, John [13 ]
Jaeger, Dirk [14 ]
Balmanoukian, Ani [9 ]
Rebelatto, Marlon C. [15 ]
Steele, Keith E. [15 ]
Jin, Xiaoping [15 ]
Robbins, Paul B. [15 ]
Blake-Haskins, John A. [15 ]
Segal, Neil H. [16 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Columbia Univ, Med Ctr, New York, NY USA
[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[4] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA
[5] Georgia Regent Univ, GRU Canc Ctr, Agusta, MD USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[8] Leuven Canc Inst, Leuven, Belgium
[9] Angeles Clin & Res Inst, Los Angeles, CA USA
[10] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[11] Mt Sinai Med Ctr, New York, NY 10029 USA
[12] Univ Hosp Siena, Siena, Italy
[13] Mary Crowley Canc Res Ctr, Dallas, TX USA
[14] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany
[15] Medlmmune, Gaithersburg, MD USA
[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER IMMUNOLOGY RESEARCH | 2016年 / 4卷 / 01期
关键词：
D O I：
10.1158/2326-6074.CRICIMTEATIAACR15-A047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A047
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)
    Haigentz, Missak
    Nemunaitis, John
    Johnson, Melissa
    Mohindra, Nisha
    Eaton, Keith
    Patel, Manish
    Awad, Mark
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Potvin, Diane
    Neskorik, Tavette
    Levisetti, Matteo
    Garon, Edward
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1073 - S1074
  • [42] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
    Zeng, Tian
    Qin, Qin
    Bian, Zhiheng
    Li, Jianjun
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201
  • [43] Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Sequist, Lecia V.
    Shaw, Alice Tsang
    Azzoli, Christopher G.
    Piotrowska, Zofia
    Huynh, Tiffany
    Fulton, Linnea
    Schultz, Katherine
    Hata, Aaron N.
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer
    Schabath, Matthew B.
    Dalvi, Tapashi B.
    Dai, Hongyue A.
    Crim, Alan L.
    Midha, Anita
    Shire, Norah
    Gimbrone, Nicholas T.
    Walker, Jill
    Greenawalt, Danielle M.
    Lawrence, David
    Rigas, James R.
    Brody, Robert
    Potter, Danielle
    Kumar, Naveen S.
    Huntsman, Shane A.
    Gray, Jhanelle E.
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9469 - 9481
  • [45] Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade
    Nie, W.
    Xu, M-D.
    Gan, L.
    Zhang, Y.
    Han, B-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [46] Programmed death-ligand (PD-L1) expression and tissue heterogeneity in advanced non-small cell lung cancer (NSCLC)
    Decatris, Marios
    Hayes, Mark
    Du Rand, Ingrid
    Ryan, Philip
    Phillips, Aled
    El-Batrawy, Sherouk
    Homewood, Renate
    Thomas, Joy
    Bowden, Caitlin
    Taniere, Phillipe
    LUNG CANCER, 2021, 156 : S29 - S30
  • [47] Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US
    Kessler, Joshua E.
    Park, Kwon N.
    Grizzle, Amy J.
    Hurwitz, Jason T.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (01) : 55 - 61
  • [48] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    MODERN PATHOLOGY, 2018, 31 : 753 - 754
  • [49] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    LABORATORY INVESTIGATION, 2018, 98 : 753 - 754
  • [50] A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
    Ott, Patrick Alexander
    Callahan, Margaret K.
    Odunsi, Kunle
    Park, Andrew J.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Karakunnel, Joyson Joseph
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345